SCHEMBL6370569

SCHEMBL6370569

Cc1cc2c(-c3ccccc3)nn(C(=O)OC(C)(C)C)c2cc1Nc1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.44
TTK P33981 1/20 0.42
MAPT P10636 3/20 0.41
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
BRD9 Q9H8M2 1/20 0.38
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FABP3 P05413 1/20 0.36
FABP4 P15090 1/20 0.36
RORC P51449 2/20 0.36
RARG P13631 1/20 0.36
TP53 P04637 1/20 0.36
MAPK8 P45983 2/20 0.36
MAPK10 P53779 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6369555 0.87 MAPK8 (0.47) MAP2K4TTKMAPTRORCRARG
SCHEMBL6369573 0.81 MAP2K4 (0.51) MAP2K4MAPTKMT2ABRD9KDM4E
SCHEMBL6378102 0.79 MAPK8 (0.46) MAP2K4TTKKDM4EALDH1A1HPGD
SCHEMBL6369561 0.78 MAP2K4 (0.46) MAP2K4MAPTKMT2ANPC1RAB9A
SCHEMBL6369498 0.77 MAP2K4 (0.49) MAP2K4TTKKMT2AALDH1A1RORC
SCHEMBL25994433 0.77 MAP2K4 (0.56) MAP2K4MAPTKMT2ARAB9ABRD9
SCHEMBL6370068 0.76 MAP2K4 (0.48) MAP2K4MAPTKMT2AKDM4EALDH1A1
SCHEMBL6370071 0.75 MAP2K4 (0.46) MAP2K4MAPTKMT2ARAB9ABRD9
SCHEMBL1513048 0.75 MAP2K4 (0.48) MAP2K4KMT2ANPC1RAB9AKDM4E
SCHEMBL22454075 0.75 MAP2K4 (0.47) MAP2K4MAPTKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP disclosed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 MAP2K4 2785/4885TTK 4053/4885MAPT 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.